University of Texas Health Science Center-Houston School of Nursing, 6901 Bertner, Room 791, Houston, TX 77030, USA.
Curr Oncol Rep. 2011 Feb;13(1):37-41. doi: 10.1007/s11912-010-0141-0.
Significant advances have been made in the identification of genes associated with the occurrence and prognosis of a variety of cancers. Recent efforts have also identified specific genomic single nucleotide polymorphisms (SNPs) that are associated with treatment toxicity in oncology, including toxicity associated with irinotecan, 5-FU, and 6-mercaptopurine. Despite the identification of these potential genomic predictors, their clinical use has been limited. Recent work has identified combined clinical characteristics and SNPs associated with toxicity with temozolomide. This combined approach may allow for identification of those at risk, and by using clinical parameters for screening, further refine those who require the more expensive genomic testing. This approach, as well as evaluation of clinical utility, economic impact, and ease of use are important components necessary for evaluation and use of genomic predictors of toxicity in the future.
在鉴定与多种癌症的发生和预后相关的基因方面已经取得了重大进展。最近的研究还确定了特定的基因组单核苷酸多态性（SNPs）与肿瘤学中的治疗毒性相关，包括与伊立替康、5-FU 和 6-巯基嘌呤相关的毒性。尽管已经确定了这些潜在的基因组预测因子，但它们的临床应用受到限制。最近的工作已经确定了与替莫唑胺毒性相关的联合临床特征和 SNPs。这种联合方法可以识别那些有风险的人，并通过使用临床参数进行筛选，进一步细化那些需要更昂贵的基因组检测的人。这种方法以及对临床效用、经济影响和易用性的评估，是未来评估和使用毒性基因组预测因子的重要组成部分。
